These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2170777)

  • 1. Immunosuppressive actions of retroviruses.
    Good RA; Ogasawara M; Liu WT; Lorenz E; Day NK
    Lymphology; 1990 Jun; 23(2):56-9. PubMed ID: 2170777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies neutralizing feline leukaemia virus (FeLV) in cats immunized with the transmembrane envelope protein p15E.
    Langhammer S; Hübner J; Kurth R; Denner J
    Immunology; 2006 Feb; 117(2):229-37. PubMed ID: 16423059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mechanism of retrovirus suppression of human T cell proliferation in vitro.
    Copelan EA; Rinehart JJ; Lewis M; Mathes L; Olsen R; Sagone A
    J Immunol; 1983 Oct; 131(4):2017-20. PubMed ID: 6311904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrovirus-mediated immunosuppression. I. FeLV-UV and specific FeLV proteins alter T lymphocyte behavior by inducing hyporesponsiveness to lymphokines.
    Orosz CG; Zinn NE; Olsen RG; Mathes LE
    J Immunol; 1985 May; 134(5):3396-403. PubMed ID: 2984289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A synthetic peptide homologous to the envelope proteins of retroviruses inhibits monocyte-mediated killing by inactivating interleukin 1.
    Kleinerman ES; Lachman LB; Knowles RD; Snyderman R; Cianciolo GJ
    J Immunol; 1987 Oct; 139(7):2329-37. PubMed ID: 2821111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of susceptibility and resistance to feline leukemia virus infection. II. Susceptibility of feline lymphocytes to productive feline leukemia virus infection.
    Rojko JL; Hoover EA; Finn BL; Olsen RG
    J Natl Cancer Inst; 1981 Oct; 67(4):899-910. PubMed ID: 6268886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and immunologic aspects of FeLV-induced immunosuppression.
    Ogilvie GK; Tompkins MB; Tompkins WA
    Vet Microbiol; 1988 Jul; 17(3):287-96. PubMed ID: 2847393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrovirus-mediated immunosuppression. II. FeLV-UV alters in vitro murine T lymphocyte behavior by reversibly impairing lymphokine secretion.
    Orosz CG; Zinn NE; Olsen RG; Mathes LE
    J Immunol; 1985 Jul; 135(1):583-90. PubMed ID: 2987350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro inhibition of feline leukaemia virus infection by synthetic peptides derived from the transmembrane domain.
    Boenzli E; Robert-Tissot C; Sabatino G; Cattori V; Meli ML; Gutte B; Rovero P; Flynn N; Hofmann-Lehmann R; Lutz H
    Antivir Ther; 2011; 16(6):905-13. PubMed ID: 21900723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retroviruses associated with leukemia and ablative syndromes in animals and in human beings.
    Essex M; McLane MF; Kanki P; Allan J; Kitchen L; Lee TH
    Cancer Res; 1985 Sep; 45(9 Suppl):4534s-4538s. PubMed ID: 2990682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New monoclonal antibodies against the putative immunosuppressive site of retroviral p15E.
    Lang MS; Oostendorp RA; Simons PJ; Boersma W; Knegt P; van Ewijk W
    Cancer Res; 1994 Apr; 54(7):1831-6. PubMed ID: 7511054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subunit vaccines against exogenous retroviruses: overview and perspectives.
    Hunsmann G
    Cancer Res; 1985 Sep; 45(9 Suppl):4691s-4693s. PubMed ID: 2410114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of protective immune response in cats by vaccination with feline leukemia virus iscom.
    Osterhaus A; Weijer K; Uytdehaag F; Jarrett O; Sundquist B; Morein B
    J Immunol; 1985 Jul; 135(1):591-6. PubMed ID: 2987351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of endogenous and exogenous feline leukemia virus sequences by real-time PCR assays.
    Tandon R; Cattori V; Willi B; Lutz H; Hofmann-Lehmann R
    Vet Immunol Immunopathol; 2008 May; 123(1-2):129-33. PubMed ID: 18295344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralising antibodies against the transmembrane protein of feline leukaemia virus (FeLV).
    Langhammer S; Fiebig U; Kurth R; Denner J
    Vaccine; 2005 May; 23(25):3341-8. PubMed ID: 15837241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A targeted mutation within the feline leukemia virus (FeLV) envelope protein immunosuppressive domain to improve a canarypox virus-vectored FeLV vaccine.
    Schlecht-Louf G; Mangeney M; El-Garch H; Lacombe V; Poulet H; Heidmann T
    J Virol; 2014 Jan; 88(2):992-1001. PubMed ID: 24198407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retroviral-associated eosinophilic leukemia in the cat.
    Lewis MG; Kociba GJ; Rojko JL; Stiff MI; Haberman AB; Velicer LF; Olsen RG
    Am J Vet Res; 1985 May; 46(5):1066-70. PubMed ID: 2988377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clearance of retroviremia and regression of malignancy in cats with leukemia-lymphoma during treatment with staphylococcal protein A.
    Engelman RW; Good RA; Day NK
    Cancer Detect Prev; 1987; 10(5-6):435-44. PubMed ID: 3032440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immunosuppressive peptide of HIV-1: functional domains and immune response in AIDS patients.
    Denner J; Norley S; Kurth R
    AIDS; 1994 Aug; 8(8):1063-72. PubMed ID: 7986401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro immunomodulation and in vivo immunotherapy of retrovirus-induced immunosuppression.
    Good RA; Haraguchi S; Lorenz E; Day NK
    Int J Immunopharmacol; 1991; 13 Suppl 1():1-7. PubMed ID: 1668553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.